BIIB - Biogen Inc Stock Analysis
Biogen Inc (BIIB) is a publicly traded company listed on the . It operates in the industry, part of the broader sector. The company has a market capitalization of 30.48B, generates annual revenue of 9.66B, and reports net income of 834.60M. As of the latest data, the stock is trading at 206.28 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. This stock does not currently pay a dividend. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.86), indicating current market sentiment. Institutional ownership is reported at 98.48%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 59.49%, trading within a 52-week range of 127.00 - 219.72.
BIIB - Biogen Inc
206.28
Analyst Consensus
Hold 3.86
BIIB – Analyst Rating Summary
- Strong Buy: 9
- Buy: 20
- Hold: 13
- Sell: 1
- Strong Sell: 0
- Total Analysts: 43
| Index: | S&P 500 | P/E: | 36.53 | EPS (ttm): | 5.65 | Insider Own: | 0.89% | Shs Outstand: | 147.70M | Perf Week: | -0.79% |
| Market Cap: | 30.48B | Forward P/E: | 12.43 | EPS next Y: | 16.59 | Insider Trans: | -0.29% | Shs Float: | 146.43M | Perf Month: | 2.95% |
| Income(ttm): | 834.60M | PEG: | 1.77 | EPS next Q: | 2.09 | Inst Own: | 98.48% | Short Float: | 4.10% | Perf Quarter: | 8.18% |
| Revenue(ttm): | 9.66B | P/S: | 3.15 | EPS this Y: | -17.81% | Inst Trans: | -1.94% | Short Ratio: | 4.77 | Perf Half Y: | 11.23% |
| Book/sh: | 127.61 | P/B: | 1.62 | EPS next Y: | 32.10% | ROA: | 2.76% | Short Interest: | 6.00M | Perf Year: | 59.49% |
| Cash/sh: | 8.70 | P/C: | 23.72 | EPS next 5Y: | 7.03% | ROE: | 4.58% | 52W Range: | 127.00 - 219.72 | Perf YTD: | 17.21% |
| Dividend Est.: | - | P/FCF: | 11.30 | EPS past 3/5Y: | -25.04% -18.74% | ROIC: | 3.16% | 52W High: | 219.72 -6.12% | Beta: | 0.17 |
| Dividend TTM: | - | Quick Ratio: | 1.26 | Sales past 3/5Y: | 0.35% -5.06% | Gross Margin: | 64.29% | 52W Low: | 127.00 62.43% | Perf 5Y: | -39.33% |
| Dividend Ex-Date: | - | Current Ratio: | 1.87 | EPS Y/Y TTM: | -45.79% | Oper. Margin: | 19.50% | RSI (14): | 52.63 | Volatility: | 3.26% 4.08% |
| Employees: | 7500 | Debt/Eq: | 0.44 | Sales Y/Y TTM: | 0.53% | Profit Margin: | 8.64% | Recom: | 1.89 | Target Price: | 237.28 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.40 | EPS Q/Q: | -84.85% | Payout: | 0.00% | Rel Volume: | 0.71 | Prev Close: | 206.63 |
| Sales Surprise: | 11.20% | EPS Surprise: | 22.49% | Sales Q/Q: | 2.38% | Earnings: | Jul 29 BMO | Avg Volume: | 1.26M | Price: | 206.28 |
| SMA20: | 1.49% | SMA50: | 2.27% | SMA200: | 11.75% | Undervalued: 15.03% | Volume: | 892,772 | Change: | -0.17% | |
Graham Classic formula value: 114.46
(P/E=8 * 1g) Min value: 76.25
(current P/E * 2g) Max value: 256.67
Average value: 149.13
About Biogen Inc
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.